Evidence map›Paper›PMID 40565068›Full record

ArticleInternational journal of molecular sciences2025

Neuroprotective Potential of Betulin and Its Drug Formulation with Cyclodextrin-In Vitro Assessment.

Agnieszka Zakrzeska, Agnieszka Kołodziejczyk, Piotr Komorowski, Paulina Sokołowska, Bożena Rokita, Radosław A Wach, Małgorzata Siatkowska

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Agnieszka ZakrzeskaDepartment of Nursing, University of Medical Science in Bialystok, Krakowska 9, 15-875 Bialystok, Poland.
Agnieszka KołodziejczykLaboratory of Molecular and Nanostructural Biophysics, Bionanopark, 114/116 Dubois, 93-465 Lodz, Poland.ORCID 0000-0003-3184-4831
Piotr KomorowskiLaboratory of Molecular and Nanostructural Biophysics, Bionanopark, 114/116 Dubois, 93-465 Lodz, Poland.ORCID 0000-0002-4035-7501
Paulina SokołowskaDepartment of Pharmacology and Toxicology, Medical University of Lodz, 7/9 Zeligowskiego, 90-752 Lodz, Poland.
Bożena RokitaBioMatGel, Pienista 41F/11, 94-109 Lodz, Poland.
Radosław A WachBioMatGel, Pienista 41F/11, 94-109 Lodz, Poland.ORCID 0000-0001-7311-4525
Małgorzata SiatkowskaLaboratory of Molecular and Nanostructural Biophysics, Bionanopark, 114/116 Dubois, 93-465 Lodz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Central nervous system disorders, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, are associated with complex pathophysiological mechanisms involving oxidative stress, inflammation, and protein misfolding. According to the literature, betulin, a natural compound derived from the bark of birch trees, demonstrates promising neuroprotective effects. This study investigates the neuroprotective potential of betulin and its complex with cyclodextrin, referred to as Betula Forte, using an in vitro model of differentiated SH-SY5Y neuroblastoma cells. Specifically, the study explores the antioxidant and antiapoptotic properties of these compounds under oxidative stress induced by hydrogen peroxide (H

Indexed as

CyclodextrinsNeuroprotective AgentsTriterpenesAntioxidantsApoptosisBetulinic AcidCell Line, TumorCell SurvivalDrug CompoundingHumansHydrogen PeroxideOxidative StressReactive Oxygen SpeciesAntioxidantsbetulinBetulinic AcidCyclodextrinsHydrogen PeroxideNeuroprotective AgentsReactive Oxygen SpeciesTriterpenesapoptosisbetulindifferentiated neuroblastoma cellsneuroprotectionROSSH-SY5Y

Identifiers

PMID40565068
PMCPMC12192872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.